BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22297721)

  • 21. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
    Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
    Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
    Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
    Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
    Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
    Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.
    Dong HJ; Fang C; Wang L; Fan L; Xu J; Wu JZ; Lu TX; Li JY; Xu W
    Med Oncol; 2014 Apr; 31(4):908. PubMed ID: 24615009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Chin-Yee B; Sadikovic B; Chin-Yee IH
    Br J Haematol; 2020 Mar; 188(5):652-660. PubMed ID: 30836431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 dysfunction in CLL: Implications for prognosis and treatment.
    Te Raa GD; Kater AP
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):90-99. PubMed ID: 27742075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
    Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
    Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.
    Pekova S; Mazal O; Cmejla R; Hardekopf DW; Plachy R; Zejskova L; Haugvicova R; Jancuskova T; Karas M; Koza V; Smolej L; Bezdickova L; Kozak T
    Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
    Mohr J; Helfrich H; Fuge M; Eldering E; Bühler A; Winkler D; Volden M; Kater AP; Mertens D; Te Raa D; Döhner H; Stilgenbauer S; Zenz T
    Blood; 2011 Feb; 117(5):1622-32. PubMed ID: 21115975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency Of TP53 Gene Mutation In Patients With Chronic Lymphocytic Leukaemia.
    Qadir H; Nasir N; Qadir N; Adil SN; Tanzeem H; Qadir A
    J Ayub Med Coll Abbottabad; 2020; 32(4):523-526. PubMed ID: 33225656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep targeted sequencing of
    Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
    Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
    Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
    Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
    Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
    Thornton PD; Gruszka-Westwood AM; Hamoudi RA; Atkinson S; Kaczmarek P; Morilla RM; Hilditch BL; A'Hern R; Matutes E; Catovsky D
    Hematol J; 2004; 5(1):47-54. PubMed ID: 14745430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
    Shindiapina P; Brown JR; Danilov AV
    Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
    Zenz T; Mohr J; Edelmann J; Sarno A; Hoth P; Heuberger M; Helfrich H; Mertens D; Dohner H; Stilgenbauer S
    Leuk Lymphoma; 2009 Mar; 50(3):510-3. PubMed ID: 19347737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
    Sivina M; Kim E; Wierda WG; Ferrajoli A; Jain N; Thompson P; Kantarjian H; Keating M; Burger JA
    Blood; 2021 Dec; 138(24):2589-2592. PubMed ID: 34521099
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of locus specific sub-clone separation by fluorescence in situ hybridization in suspension in chronic lymphocytic leukemia.
    Do CH; Bailey S; Macardle C; Thurgood LA; Lower KM; Kuss BJ
    Cytometry A; 2017 Nov; 91(11):1088-1095. PubMed ID: 29024486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.
    Minervini CF; Cumbo C; Orsini P; Brunetti C; Anelli L; Zagaria A; Minervini A; Casieri P; Coccaro N; Tota G; Impera L; Giordano A; Specchia G; Albano F
    Diagn Pathol; 2016 Oct; 11(1):96. PubMed ID: 27724982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.